An observational study in Mature B-Cell Neoplasm, sponsored by Oncology Institute of Southern Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Oncology Institute of Southern Switzerland · Observational
Among 51 studies in Lymphoma, Large B-Cell, Diffuse with a site in Switzerland — 4 open to participants now, 10 under way, 5 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Switzerland.
Among the 51 studies in Lymphoma, Large B-Cell, Diffuse with a site in Switzerland, this one is one of 2 that started in 2017, is one of 4 observational ones, and was the 35th registered.
1,869 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 356 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →4 of the 51 studies in Lymphoma, Large B-Cell, Diffuse with a site in Switzerland are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Switzerland, United States, Argentina and 32 more countries
Ages 18+
Nurix Therapeutics, Inc. · Sites in Switzerland, United States, France and 5 more countries
Ages 18+
International Extranodal Lymphoma Study Group (IELSG) · Sites in Switzerland, Italy
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 50 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 25
First in 1994; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 444 is above the median of 150 across 185 observational studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 240 across the 47 interventional studies, 374 across the 4 observational. Of the 37 that completed or were terminated, 11 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 51 have an industry lead sponsor. The 10 most frequent:
Oncology Institute of Southern Switzerland is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Oncology Institute of Southern Switzerland has 2 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
2 of the studies in Lymphoma, Large B-Cell, Diffuse with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05131022Nurix Therapeutics, Inc.A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies in Lymphoma, Large B-Cell, Diffuse with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.
Clinical data and peripheral blood samples (20 ml in EDTA tubes and 20 ml in Cell-Free DNA BCT tubes) will be collected during the clinico/laboratory visits that are planned as per clinical routine at the time of mature B-cell tumor diagnosis, before treatment, at the time of interim PET/CT, at the time of end of treatment PET/CT and at the time of disease relapse.
Clinical variables, international prognostic index, results of plasma cell free DNA genotyping and of PET-CT will be analyzed descriptively.
The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the compiled results of plasma cell free DNA genotyping and interim PET-CT (for cHL and DLBCL), or plasma cell free DNA genotyping and baseline international prognostic index (for FL and MCL) in identifying patients that are progression free for >24 months after first line therapy will be calculated and compared with those obtained by the sole interim PET-CT (cHL and DLBCL) or the sole international prognostic index (FL, MCL).
Male or female adults 18 years or older with a documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
Accuracy of interim plasma cell free DNA genotyping for cHL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of cured vs non cured patients in cHL (patients not progressed after 24 months)
Time frame: 24 months from treatment
Accuracy of interim plasma cell free DNA genotyping for DLBCL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of cured vs non cured patients in DLBCL (patients not progressed after 24 months)
Time frame: 24 months from treatment
Accuracy of interim plasma cell free DNA genotyping for FL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of patients in continuous complete remission at 24 months from first line treatment vs patients not in continuous complete remission at 24 months from first line treatment in FL and other indolent B-cell lymphoproliferative disorders
Time frame: 24 months from treatment
Accuracy of interim plasma cell free DNA genotyping for MCL patients
Assessment of interim plasma cell free DNA genotyping accuracy in the identification of patients in continuous complete remission at 24 months from first line treatment vs patients not in continuous complete remission at 24 months from first line treatment in MCL
Time frame: 24 months from treatment
Started Sep 2017 (actual). Primary completion is estimated for Dec 2027, 123 months after the start.
Of 52 non-industry observational studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's planned 123 months is above that.
Counting every sponsor, half of 66 studies reached it within 52 months; a quarter within 29 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large B-Cell, Diffuse →
Oncology Institute of Southern Switzerland